The sequential use of abiraterone and enzalutamide (MDV3100) in castrate resistant prostate cancer patients: Experience from Birmingham, United Kingdom.

被引：0
|
作者：
Stevenson, Robert
Ford, Daniel
Zarkar, Anjali M.
Glaholm, John
Porfiri, Emilio
Tew, Alice
El-Modir, Ahmed
James, Nicholas David
机构：
[1] Univ Hosp Birmingham, Birmingham, W Midlands, England
[2] Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England
[3] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England
[4] Univ Birmingham, Sch Canc Sci, Birmingham, W Midlands, England
[5] Univ Birmingham, Birmingham, W Midlands, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16048
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer (mCRPC): Results from an expanded access program
    Thomson, David
    Charnley, Natalie
    Parikh, Omi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [22] SURVIVAL RATES AND ECONOMIC OUTCOMES IN CHEMOTHERAPY-NAIVE METASTATIC CASTRATE RESISTANT PROSTATE CANCER PATIENTS TREATED WITH ABIRATERONE ACETATE OR ENZALUTAMIDE
    Ramaswamy, Krishnan
    Lechpammer, Stanislav
    Mardekian, Jack
    Schultz, Neil M.
    Huang, Ahong
    Wang, Li
    Baser, Onur
    George, Daniel
    JOURNAL OF UROLOGY, 2019, 201 (04): : E242 - E243
  • [23] Clusterin knockdown synergizes activity of second generation anti-androgen, MDV3100, through enhancing AR degradation and repression of FKBP52 in castrate resistant prostate cancer model
    Matsumoto, H.
    Kuruma, H.
    Zoubeidi, A.
    Zardan, A.
    Fazli, L.
    Ettinger, S.
    Matsuyama, H.
    Gleave, M.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E235 - E235
  • [24] CLINICAL FACTORS INFLUENCING USE OF ABIRATERONE AND ENZALUTAMIDE (A/E) IN HORMONE RESISTANT PROSTATE CANCER: REAL-WORLD EXPERIENCE
    Lui, Andrew
    Aherne, Noel J.
    Westhuyzen, Justin
    Tulloh, Sandy
    Briscoe, Karen P.
    Jain, Ankit
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 127 - 127
  • [25] Statin type and survival of patients with metastatic castrate-resistant prostate cancer receiving abiraterone and enzalutamide: A nationwide retrospective cohort study.
    Yoon, Harrison
    Luo, Suhong
    Sanfilippo, Kristen Marie
    Linneman, Travis
    Whitmer, Alison
    Schoen, Martin W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [26] Comparative cardiovascular risk associated with enzalutamide and abiraterone use in patients with metastatic castration-resistant prostate cancer
    Cheng, Yue
    Delcher, Chris
    Moga, Daniela C.
    Huang, Bin
    Adams, Val
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 106 - 107
  • [27] Abiraterone acetate in comparison to enzalutamide in African American patients with metastatic castrate resistant prostate cancer: A single-center retrospective study.
    Telfah, Mohammad
    Holzbeierlein, Jeffrey M.
    Shen, Xinglei
    Wulff-Burchfield, Elizabeth Marie
    Parikh, Rahul Atul
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Radium-223 therapy in symptomatic metastatic castrate resistant prostate cancer (mCRPC) - sequential use post-abiraterone/prednisolone
    Jiang, Xue Yan
    Atkinson, Sarah
    Cumming, Sam
    Burns, Alexander
    Pearson, Rachel
    Frew, John
    McMenemin, Rhona
    Azzabi, Ashraf
    Leaning, Darren
    Pedley, Ian
    CLINICAL ONCOLOGY, 2019, 31 : E10 - E11
  • [29] Overall survival beyond first-line docetaxel in patients with metastatic castrate-resistant prostate cancer treated with abiraterone acetate or enzalutamide.
    Heo, Mi Hwa
    Park, Se Hoon
    Kim, Hee Kyung
    Cho, Jinhyun
    Kim, Youjin
    Lee, Hansang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [30] Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamide
    Jang, Albert
    Lanka, Sree M.
    Huang, Minqi
    Casado, Crystal V.
    Caputo, Sydney A.
    Sweeney, Patrick L.
    Gupta, Kanika
    Pocha, Olivia
    Habibian, Nicholas
    Hawkins, Madeline E.
    Lieberman, Alexandra D.
    Schwartz, Jennifer
    Jaeger, Ellen B.
    Miller, Patrick J.
    Layton, Jodi L.
    Barata, Pedro C.
    Lewis, Brian E.
    Ledet, Elisa M.
    Sartor, Oliver
    PROSTATE, 2023, 83 (11): : 1028 - 1034
12345